The Cognitive Link between in Utero Nutrition and Schooling: Experimental Evidence from Tanzania
How to cite
Nikolov, Plamen. 2014. "The Cognitive Link between in Utero Nutrition and Schooling: Experimental Evidence from Tanzania." AEA RCT Registry. AEARCTR-0000145. https://doi.org/10.1257/rct.145-3.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Because of the high returns of schooling in developing countries, policy-makers have placed considerable attention to increasing school access. However, an important mechanism through which brain development in utero can affect demand for education exists. Cognitive development in utero, due to maternal deficiency in folic acid, can biologically constrain children’s demand for education. Using a more scientifically credible research designed to detect causal effects than has been used in previous research, we examine how reductions in micronutrient deficiency in utero impact subsequent child schooling attainment in Tanzania. We also examine to what extent parents allocate resources so as to compensate for or to reinforce inequalities across children in cognitive endowments. Capturing the behavioral response to the biological intervention allows us to disentangle the biological effect from the household response to the original randomized intervention. To execute this strategy, we follow up on a randomized control trial with micronutrient supplements offered to HIV-negative pregnant women in Dar es Salaam, Tanzania between 2001-2003. While data collection is still ongoing, very preliminary results show cognitive improvements among children born to mothers in the micronutrient supplementation group from the original RCT.
Intervention
The double-blind trial, assigning 8468 pregnant women to receive a daily oral dose of either a micronutrient supplement or placebo, examined the effect of nutrient supplementation on low birth weight (<2500g), prematurity, and fetal death. The randomized trial started between 2001-2004 with pregnant women in Dar es Salaam, Tanzania to account for differences in physical health outcomes at birth for children. Pregnant women who attended antenatal clinicsAccording to a DHS 1996 (Bureau of Statistics, 1996), 97% of pregnant women attend antenatal care (ANC), and 70% do so at least four times. in Dar es Salaam, Tanzania, between August 2001 and July 2004 were invited to participate in the trial. Simple random sampling was used. Requirements for eligibility included a negative test for HIV infection, a plan to stay in the city until delivery and for 1 year thereafter, and an estimated gestational age between 6 and 27 weeks according to the date of the last menstrual period. A list was prepared according to a randomization sequence in blocks of 20; at enrollment, each eligible woman was assigned to the next numbered bottle. The treatment tablet included 20 mg of micronutrient B2, 25 mg of micronutrient B6, 50 mg of micronutrient B12, and 0.8 mg of B9 (folic acid).The active tablets and placebo were similar in shape, size, and color and were packaged in identical coded bottles.Average take up rate of treatment in the original RCT was 0.88.
Experimental design
The double-blind trial, assigning 8468 pregnant women to receive a daily oral dose of either a micronutrient supplement or placebo, examined the effect of nutrient supplementation on low birth weight (<2500g), prematurity, and fetal death. The randomized trial started between 2001-2004 with pregnant women in Dar es Salaam, Tanzania to account for differences in physical health outcomes at birth for children. Pregnant women who attended antenatal clinicsAccording to a DHS 1996 (Bureau of Statistics, 1996), 97% of pregnant women attend antenatal care (ANC), and 70% do so at least four times. in Dar es Salaam, Tanzania, between August 2001 and July 2004 were invited to participate in the trial. Simple random sampling was used. Requirements for eligibility included a negative test for HIV infection, a plan to stay in the city until delivery and for 1 year thereafter, and an estimated gestational age between 6 and 27 weeks according to the date of the last menstrual period. A list was prepared according to a randomization sequence in blocks of 20; at enrollment, each eligible woman was assigned to the next numbered bottle. The treatment tablet included 20 mg of micronutrient B2, 25 mg of micronutrient B6, 50 mg of micronutrient B12, and 0.8 mg of B9 (folic acid).The active tablets and placebo were similar in shape, size, and color and were packaged in identical coded bottles.Average take up rate of treatment in the original RCT was 0.88.
Design details
Cited by
No citation data available for this registration yet.